Memorial Sloan Kettering Cancer Center
2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 and for Which Pts? Does E1912 Suggest Ibrutinib Can Be Considered a Time Limited Therapy?
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Anthony R. Mato
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Anthony R. Mato
Login to view comments.
Click here to Login